Iovance Biotherapeutics Stock Forecast, Price & News

+1.31 (+5.30 %)
(As of 06/24/2021 01:51 PM ET)
Today's Range
50-Day Range
52-Week Range
Volume154,542 shs
Average Volume2.75 million shs
Market Capitalization$3.98 billion
P/E RatioN/A
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive IOVA News and Ratings via Email

Sign-up to receive the latest news and ratings for Iovance Biotherapeutics and its competitors with MarketBeat's FREE daily newsletter.

Iovance Biotherapeutics logo

About Iovance Biotherapeutics

Iovance Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. It has six ongoing phase 2 clinical studies, including C-144-01, of its lead product candidate, lifileucel, for the treatment of metastatic melanoma; C-145-04, of its product candidate lifileucel for recurrent, metastatic, or persistent cervical cancer; and C-145-03, of its product candidate LN-145, for recurrent and/or metastatic head and neck squamous cell carcinoma. Iovance Biotherapeutics, Inc. has collaborations and licensing agreements with H. Lee Moffitt Cancer Center; M.D. Anderson Cancer Center; Ohio State University; Centre hospitalier de l'Université de Montreal; Cellectis S.A.; and Novartis Pharma AG. The company was formerly known as Lion Biotechnologies, Inc. and changed its name to Iovance Biotherapeutics, Inc. in June 2017. Iovance Biotherapeutics, Inc. was incorporated in 2007 and is headquartered in San Carlos, California.


See More Headlines

Industry, Sector and Symbol

Sales & Book Value






Overall MarketRank

1.52 out of 5 stars

Medical Sector

547th out of 2,105 stocks

Biological Products, Except Diagnostic Industry

83rd out of 198 stocks

Analyst Opinion: 4.4Community Rank: 3.2Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

Iovance Biotherapeutics (NASDAQ:IOVA) Frequently Asked Questions

Is Iovance Biotherapeutics a buy right now?

13 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Iovance Biotherapeutics in the last year. There are currently 3 hold ratings and 10 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Iovance Biotherapeutics stock.
View analyst ratings for Iovance Biotherapeutics
or view top-rated stocks.

What stocks does MarketBeat like better than Iovance Biotherapeutics?

Wall Street analysts have given Iovance Biotherapeutics a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Iovance Biotherapeutics wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Iovance Biotherapeutics' next earnings date?

Iovance Biotherapeutics is scheduled to release its next quarterly earnings announcement on Thursday, August 5th 2021.
View our earnings forecast for Iovance Biotherapeutics

How were Iovance Biotherapeutics' earnings last quarter?

Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) released its earnings results on Thursday, May, 6th. The biotechnology company reported ($0.51) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.48) by $0.03.
View Iovance Biotherapeutics' earnings history

How has Iovance Biotherapeutics' stock price been impacted by COVID-19?

Iovance Biotherapeutics' stock was trading at $29.58 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, IOVA shares have decreased by 12.3% and is now trading at $25.94.
View which stocks have been most impacted by COVID-19

What price target have analysts set for IOVA?

13 Wall Street analysts have issued 12 month target prices for Iovance Biotherapeutics' stock. Their forecasts range from $18.00 to $55.00. On average, they anticipate Iovance Biotherapeutics' stock price to reach $41.00 in the next twelve months. This suggests a possible upside of 58.1% from the stock's current price.
View analysts' price targets for Iovance Biotherapeutics
or view top-rated stocks among Wall Street analysts.

Who are Iovance Biotherapeutics' key executives?

Iovance Biotherapeutics' management team includes the following people:
  • Dr. Frederick G. Vogt Ph.D., Esq., Interim Pres, CEO, Gen. Counsel & Corp. Sec. (Age 47, Pay $515.4k)
  • Mr. Jean-Marc Bellemin M.B.A., Chief Financial Officer & Principal Accounting Officer (Age 49, Pay $580k)
  • Dr. Friedrich Graf Finckenstein M.D., Chief Medical Officer (Age 54, Pay $551.4k)
  • Dr. Igor P. Bilinsky, Chief Operating Officer (Age 48)
  • Ms. Sara Pellegrino, VP of Investor Relations & PR
  • Mr. Howard B. Johnson, Sr. VP of Corp. Devel., Alliance Management & Program Management (Age 61)
  • James Ziegler, Sr. VP of Commercial
  • Dr. Elma S. Hawkins, Advisor to the Board (Age 64)

Who are some of Iovance Biotherapeutics' key competitors?

What other stocks do shareholders of Iovance Biotherapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Iovance Biotherapeutics investors own include Applied Materials (AMAT), Portola Pharmaceuticals (PTLA), (KDMN), Immunomedics (IMMU), Bristol-Myers Squibb (BMY), Seagen (SGEN), CA (CA), Advanced Micro Devices (AMD), BlackRock (BLK) and Novavax (NVAX).

What is Iovance Biotherapeutics' stock symbol?

Iovance Biotherapeutics trades on the NASDAQ under the ticker symbol "IOVA."

Who are Iovance Biotherapeutics' major shareholders?

Iovance Biotherapeutics' stock is owned by many different retail and institutional investors. Top institutional investors include ARK Investment Management LLC (12.91%), Franklin Resources Inc. (5.90%), BlackRock Inc. (5.90%), Perceptive Advisors LLC (5.66%), Nikko Asset Management Americas Inc. (3.51%) and Sumitomo Mitsui Trust Holdings Inc. (3.61%).
View institutional ownership trends for Iovance Biotherapeutics

Which major investors are selling Iovance Biotherapeutics stock?

IOVA stock was sold by a variety of institutional investors in the last quarter, including Price T Rowe Associates Inc. MD, Lord Abbett & CO. LLC, Perceptive Advisors LLC, Rothschild & Co. Asset Management US Inc., Victory Capital Management Inc., Sei Investments Co., WCM Investment Management LLC, and Allianz Asset Management GmbH.
View insider buying and selling activity for Iovance Biotherapeutics
or view top insider-selling stocks.

Which major investors are buying Iovance Biotherapeutics stock?

IOVA stock was acquired by a variety of institutional investors in the last quarter, including ARK Investment Management LLC, Credit Suisse AG, Goldman Sachs Group Inc., Nikko Asset Management Americas Inc., Sumitomo Mitsui Trust Holdings Inc., Alliancebernstein L.P., JPMorgan Chase & Co., and Morgan Stanley.
View insider buying and selling activity for Iovance Biotherapeutics
or or view top insider-buying stocks.

How do I buy shares of Iovance Biotherapeutics?

Shares of IOVA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Iovance Biotherapeutics' stock price today?

One share of IOVA stock can currently be purchased for approximately $25.94.

How much money does Iovance Biotherapeutics make?

Iovance Biotherapeutics has a market capitalization of $3.96 billion. The biotechnology company earns $-259,580,000.00 in net income (profit) each year or ($1.88) on an earnings per share basis.

How many employees does Iovance Biotherapeutics have?

Iovance Biotherapeutics employs 241 workers across the globe.

What is Iovance Biotherapeutics' official website?

The official website for Iovance Biotherapeutics is

Where are Iovance Biotherapeutics' headquarters?

Iovance Biotherapeutics is headquartered at 999 SKYWAY ROAD SUITE 150, SAN CARLOS CA, 94070.

How can I contact Iovance Biotherapeutics?

Iovance Biotherapeutics' mailing address is 999 SKYWAY ROAD SUITE 150, SAN CARLOS CA, 94070. The biotechnology company can be reached via phone at (650) 260-7120 or via email at [email protected]

This page was last updated on 6/24/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.